NasdaqCM:TGTXBiotechs
A Look at TG Therapeutics’s Valuation Following New Phase 3 Trial Enrollment for BRIUMVI Expansion
Here’s something worth your attention if you’ve been considering what comes next for TG Therapeutics (TGTX). The company just kicked off enrollment for a Phase 3 trial testing subcutaneous BRIUMVI in people with relapsing multiple sclerosis. This is not just another checkpoint; this milestone carries significant importance for shareholders as it expands the reach of a product that is already approved in the US, Europe, UK, Switzerland, and Australia. Investors are watching closely to see if...